Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of “Hold” from Analysts

Shares of Biogen Inc. (NASDAQ:BIIB) have received an average rating of “Hold” from the twenty-seven ratings firms that are covering the stock, MarketBeat.com reports. Fifteen investment analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $205.0385.

Several brokerages recently commented on BIIB. Royal Bank Of Canada raised their price objective on shares of Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a research note on Monday, February 9th. Guggenheim increased their target price on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a report on Monday, February 9th. Piper Sandler lifted their price target on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. HSBC reissued a “reduce” rating and set a $143.00 price target (down from $144.00) on shares of Biogen in a research note on Wednesday, December 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th.

Biogen Stock Down 1.4%

Biogen stock opened at $188.02 on Friday. The stock’s 50 day moving average price is $181.64 and its 200 day moving average price is $162.83. Biogen has a 1-year low of $110.04 and a 1-year high of $202.41. The company has a market cap of $27.59 billion, a PE ratio of 21.34, a price-to-earnings-growth ratio of 1.51 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts predict that Biogen will post 15.83 EPS for the current fiscal year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Elevation Point Wealth Partners LLC purchased a new position in shares of Biogen during the 2nd quarter worth about $25,000. WPG Advisers LLC increased its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the last quarter. Rothschild Investment LLC raised its stake in Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares during the period. Accredited Wealth Management LLC boosted its holdings in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares during the last quarter. Finally, First Horizon Corp purchased a new stake in shares of Biogen during the 4th quarter valued at $30,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.